These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34138563)

  • 1. Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A
    de Gaetano M; Tighe C; Gahan K; Zanetti A; Chen J; Newson J; Cacace A; Marai M; Gaffney A; Brennan E; Kantharidis P; Cooper ME; Leroy X; Perretti M; Gilroy D; Godson C; Guiry PJ
    J Med Chem; 2021 Jul; 64(13):9193-9216. PubMed ID: 34138563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
    de Gaetano M; Butler E; Gahan K; Zanetti A; Marai M; Chen J; Cacace A; Hams E; Maingot C; McLoughlin A; Brennan E; Leroy X; Loscher CE; Fallon P; Perretti M; Godson C; Guiry PJ
    Eur J Med Chem; 2019 Jan; 162():80-108. PubMed ID: 30419493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and evaluation of novel synthetic 5-alkyl-4-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1-carbox-amide derivatives as anti-inflammatory agents.
    Shen QK; Gong GH; Li G; Jin M; Cao LH; Quan ZS
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):85-95. PubMed ID: 31707866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.
    Stama ML; Ślusarczyk J; Lacivita E; Kirpotina LN; Schepetkin IA; Chamera K; Riganti C; Perrone R; Quinn MT; Basta-Kaim A; Leopoldo M
    Eur J Med Chem; 2017 Dec; 141():703-720. PubMed ID: 29102463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation.
    Parkinson JF
    Inflamm Allergy Drug Targets; 2006 Apr; 5(2):91-106. PubMed ID: 16613568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoxin A
    Gaudin A; Tolar M; Peters OA
    Sci Rep; 2018 Jun; 8(1):8921. PubMed ID: 29892010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation.
    Maciuszek M; Ortega-Gomez A; Maas SL; Perretti M; Merritt A; Soehnlein O; Chapman TM
    Eur J Med Chem; 2021 Mar; 214():113194. PubMed ID: 33548634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoxin A(4) reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation.
    Kure I; Nishiumi S; Nishitani Y; Tanoue T; Ishida T; Mizuno M; Fujita T; Kutsumi H; Arita M; Azuma T; Yoshida M
    J Pharmacol Exp Ther; 2010 Feb; 332(2):541-8. PubMed ID: 19846590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
    Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM
    Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor.
    Maddox JF; Hachicha M; Takano T; Petasis NA; Fokin VV; Serhan CN
    J Biol Chem; 1997 Mar; 272(11):6972-8. PubMed ID: 9054386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual modulation of formyl peptide receptor 2 by aspirin-triggered lipoxin contributes to its anti-inflammatory activity.
    Ge Y; Zhang S; Wang J; Xia F; Wan JB; Lu J; Ye RD
    FASEB J; 2020 May; 34(5):6920-6933. PubMed ID: 32239559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of the FPR2/ALX agonist AT-01-KG in the resolution of articular inflammation.
    Galvão I; Melo EM; de Oliveira VLS; Vago JP; Queiroz-Junior C; de Gaetano M; Brennan E; Gahan K; Guiry PJ; Godson C; Teixeira MM
    Pharmacol Res; 2021 Mar; 165():105445. PubMed ID: 33493655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Airway lipoxin A4/formyl peptide receptor 2-lipoxin receptor levels in pediatric patients with severe asthma.
    Gagliardo R; Gras D; La Grutta S; Chanez P; Di Sano C; Albano GD; Vachier I; Montalbano AM; Anzalone G; Bonanno A; Riccobono L; Gjomarkaj M; Profita M
    J Allergy Clin Immunol; 2016 Jun; 137(6):1796-1806. PubMed ID: 26971688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues.
    Takano T; Clish CB; Gronert K; Petasis N; Serhan CN
    J Clin Invest; 1998 Feb; 101(4):819-26. PubMed ID: 9466977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cadmium exposure induces TNF-α-mediated necroptosis via FPR2/TGF-β/NF-κB pathway in swine myocardium.
    Zhao X; Wang S; Li X; Liu H; Xu S
    Toxicology; 2021 Apr; 453():152733. PubMed ID: 33626375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoxin A4 suppresses lipopolysaccharide-induced hela cell proliferation and migration via NF-κB pathway.
    Hao H; Xu F; Hao J; He YQ; Zhou XY; Dai H; Wu LQ; Liu FR
    Inflammation; 2015 Feb; 38(1):400-8. PubMed ID: 25348861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.
    Stalder AK; Lott D; Strasser DS; Cruz HG; Krause A; Groenen PM; Dingemanse J
    Br J Clin Pharmacol; 2017 Mar; 83(3):476-486. PubMed ID: 27730665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells.
    Ariel A; Chiang N; Arita M; Petasis NA; Serhan CN
    J Immunol; 2003 Jun; 170(12):6266-72. PubMed ID: 12794159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and
    Guo WY; Chen LZ; Shen BN; Liu XH; Tai GP; Li QS; Gao L; Ruan BF
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1678-1689. PubMed ID: 31530032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoxins, aspirin-triggered 15-epi-lipoxin stable analogs and their receptors in anti-inflammation: a window for therapeutic opportunity.
    Serhan CN; Levy BD; Clish CB; Gronert K; Chiang N
    Ernst Schering Res Found Workshop; 2000; (31):143-85. PubMed ID: 10943332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.